Kigabeq 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
R/0012 
Renewal of the marketing authorisation. 
26/04/2023 
04/07/2023 
SmPC and 
Labelling 
IA/0011 
B.III.1.a.2 - Submission of a new/updated or 
22/11/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
from an already approved manufacturer 
IB/0010/G 
This was an application for a group of variations. 
03/06/2022 
n/a 
B.I.d.1.b.1 - Stability of AS - Change in the storage 
conditions - Change to more restrictive storage 
conditions of the AS 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
B.I.c.3.b - Change in test procedure for the 
immediate packaging of the AS - Other changes to a 
test procedure (including replacement or addition) 
B.I.c.2.a - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Tightening of specification limits 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
Page 2/5 
 
 
 
 
 
 
 
 
 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/11/2021 
02/06/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/3112/
Periodic Safety Update EU Single assessment - 
06/05/2021 
n/a 
PRAC Recommendation - maintenance 
202009 
vigabatrin 
IAIN/0008/G 
This was an application for a group of variations. 
04/05/2021 
02/06/2022 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0006/G 
This was an application for a group of variations. 
11/12/2020 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.I.a.1.f - Change in the manufacturer of AS or of a 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IB/0005 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/08/2020 
30/04/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0004/G 
This was an application for a group of variations. 
18/12/2019 
30/04/2021 
SmPC and PL 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
storage conditions of the finished product - Other 
variation 
IA/0003 
B.III.1.a.2 - Submission of a new/updated or 
20/11/2019 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
22/01/2019 
09/01/2020 
SmPC and PL 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0002/G 
This was an application for a group of variations. 
15/01/2019 
09/01/2020 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
